OncoSil files US Medicare reimbursement application at US$55,000 per dose
OncoSil Medical (ASX: OSL) has submitted a Centers for Medicare & Medicaid Services (CMS) Transitional Pass-Through (TPT) Payment application on 1 September 2026 (US time) for its OncoSil™ device, seeking separate, supplemental Medicare reimbursement in the distal cholangiocarcinoma (dCCA) indication.
The filing builds directly on the FDA Humanitarian Device Exemption (HDE) approval granted on 14 August 2026 for unresectable, non-metastatic dCCA. The application was lodged at a proposed price of US$55,000 per dose, with a CMS decision and, subject to approval, an effective date targeted for 1 January 2027.
The FDA HDE approval for dCCA, granted on 14 August 2026, made the OncoSil™ device the first and only FDA-approved Class III medical device for this indication, opening an addressable US market estimated at approximately A$80 million per annum.
When big ASX news breaks, our subscribers know first
Why the CMS application matters for adoption
The TPT application seeks a distinct layer of Medicare reimbursement paid above the standard procedure reimbursement. If granted, TPT status would provide this supplemental payment for up to three years from launch, a mechanism designed to support hospital and physician adoption during the early commercialisation period.
For investors, reimbursement certainty is a central driver of hospital adoption economics. Devices that lack a clear payment pathway often face slower uptake, regardless of clinical merit. The TPT application directly addresses this hurdle for the US launch.
The reimbursement pathway also connects to OncoSil’s mandatory FDA post-approval study (PAS). TPT reimbursement is expected to support adoption at the participating academic medical centres in the PAS, facilitating early clinical utilisation following HDE approval while helping establish the foundation for broader US payer coverage over time.
| Milestone | Detail | Date | Investor Impact |
|---|---|---|---|
| CMS TPT application submitted | Seeking supplemental Medicare reimbursement | 1 Sept 2026 (US) | Advances US commercialisation |
| Proposed price | US$55,000 per dose | — | Sets reimbursement benchmark |
| CMS decision targeted | Effective same date if granted | 1 Jan 2027 | Near-term catalyst |
| TPT duration if granted | Supplemental payment up to 3 years from launch | — | Supports early adoption economics |
Nigel Lange, CEO & Managing Director
“The submission of our CMS Transitional Pass-Through application is the next critical step in our US commercialisation strategy, building directly on last month’s FDA HDE approval. Securing TPT status would give academic medical centres the reimbursement certainty they require to bring OncoSil™ to patients with dCCA quickly and lays the foundation for broader US payer coverage as we scale.”
Understanding dCCA and the OncoSil™ device
Distal cholangiocarcinoma (dCCA) is a rare form of bile duct cancer. It is often diagnosed at an advanced stage, when surgical treatment may no longer be possible, and is associated with a poor prognosis. This clinical profile positions it as a difficult-to-treat indication with limited options for many patients.
The OncoSil™ device is a single-use brachytherapy (internal radiation) device that delivers a pre-determined dose of beta radiation, using Phosphorous-32 (³²P) microparticles, directly into cancerous tissue. Its targeted approach enables a greater radiation dose to be delivered into the tumour compared with external beam radiotherapy, while sparing surrounding critical organs.
Phosphorus-32 microparticle localisation within tumour tissue was independently confirmed in a peer-reviewed histopathological study published in Pathology International, which found zero migration beyond the tumour boundary across all evaluated surgical specimens, strengthening the scientific basis for the targeted delivery mechanism.
In the United States, OncoSil™ is indicated for the treatment of unresectable, non-metastatic distal cholangiocarcinoma (dCCA), as an adjunct to systemic therapy. For investors, a targeted therapy addressing a hard-to-treat cancer, combined with Breakthrough Device recognition, underpins the commercial thesis.
The device holds the following regulatory credentials:
- CE Mark approval (European Union and United Kingdom)
- FDA HDE approval for dCCA (14 August 2026)
- Breakthrough Device designation in the United States and Europe
- Approved for sale in 30+ countries
The post-approval study and pathway to broader US distribution
The PAS is a mandatory condition of the HDE approval, designed to confirm the safety and probable benefit of the OncoSil™ device in real-world clinical use across a broader population than was studied pre-approval. It is a multicentre, prospective study with the following key parameters:
- 30 patients enrolled
- Across five academic medical centres
- Follow-up period of approximately 24 months from the last patient
The Company will engage with the FDA on pathways to widespread US distribution of the OncoSil™ device following completion of PAS enrolment (30 patients across five centres). This engagement is tied to enrolment completion, not to the conclusion of the approximately 24-month follow-up period.
For investors, TPT reimbursement is intended to facilitate early clinical utilisation during the PAS period while helping establish the reimbursement foundation for broader US payer coverage over time.
What comes next for OncoSil investors
Securing durable US reimbursement remains a critical near-term priority for OncoSil ahead of commercial launch. The roadmap sets out several catalysts for shareholders to monitor:
- CMS decision targeted for 1 January 2027
- Completion of PAS enrolment (30 patients across five centres)
- FDA engagement on widespread US distribution following completion of PAS enrolment
- Broader US payer coverage over time
The strategic logic is straightforward. TPT status, if approved, would provide time-limited supplemental Medicare payment above the standard procedure reimbursement, bridging early adoption while durable long-term US payer coverage is established.
Don’t Miss the Next Healthcare Breakthrough on ASX
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of market-moving announcements. Click the “Free Alerts” button at StockWire X to start receiving real-time alerts the moment news breaks.